Access to Genetic Counselor Services Act of 2026
Summary
S.3607 expands Medicare Part B to cover genetic counseling as a new provider category effective Jan 1, 2027, directly increasing the addressable patient population for genetic testing. This is a structural positive for Labcorp ($LH) and Quest Diagnostics ($DGX) through higher test volume, and for AMN Healthcare ($AMN) through increased demand for scarce genetic counselors. The bill is at early legislative stage (referred to Finance Committee) with companion bill HR6280 in the House.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S.3607 creates a new Medicare Part B benefit for genetic counselor services, removing a key referral bottleneck for genetic testing among 63M Medicare beneficiaries.
- 2.No new spending is appropriated; the bill authorizes coverage, with actual outlays dependent on CMS fee schedules and utilization.
- 3.Primary beneficiaries are diagnostic labs ($LH, $DGX) via increased test volume, and staffing firm $AMN via higher demand for scarce genetic counselors.
- 4.Bill is in early legislative stage (committee referral) with bipartisan sponsorship and a House companion bill; effective date of Jan 1, 2027 provides a clear timeline.
Market Implications
For $LH and $DGX, this bill is a medium-term volume catalyst not yet reflected in share prices, which have drifted slightly lower over the past month (-1.49% and -0.11% respectively). Current prices near the midpoints of their 52-week ranges suggest room for upside on legislative progress. For $AMN, which has already risen +12.43% over 30 days, the bill adds further structural support to demand for genetic counselors, though staffing revenue impact is smaller in absolute terms. Investors should watch Senate Finance Committee scheduling and any CMS preliminary fee estimates as catalysts. If the bill gains a committee hearing or markup, expect relative outperformance in these three names versus the broader healthcare market.
Full Analysis
S.3607 (Access to Genetic Counselor Services Act of 2026) was introduced on January 8, 2026 by Sen. Barrasso (R-WY) with three cosponsors: Sen. Welch (D-VT), Sen. Capito (R-WV), and Sen. Rosen (D-NV). The bill has been referred to the Senate Committee on Finance. A companion bill, HR6280, exists in the House, referred to the Energy and Commerce and Ways and Means Committees. This bicameral, bipartisan sponsorship signals moderate legislative momentum, but the bill remains in early stages — no hearings or markups have occurred.
The bill does NOT appropriate new funding. It amends the Social Security Act to add genetic counselors as a covered provider type under Medicare Part B, effective January 1, 2027. This is an authorization of coverage, not a spending authorization. The actual spending impact will depend on utilization rates by the ~63 million Medicare beneficiaries. Payment is set at 80% of the lesser of the actual charge or a fee schedule to be determined by CMS. The mechanism is regulatory — it creates a new billing category, which expands the addressable market for downstream diagnostic services.
The structural winners are diagnostic lab companies Labcorp and Quest Diagnostics. Genetic counseling is a gateway service for genetic testing — patients see a counselor, discuss risk factors, and are typically referred for a laboratory test. Currently, Medicare's coverage gap for non-physician genetic counselors creates a bottleneck; this bill removes it. Both LH and DGX have large genetic testing menus (hereditary cancer panels, prenatal screening, pharmacogenomics) that directly benefit from increased counseling-driven orders. AMN Healthcare benefits as the primary pure-play staffing provider for allied health; genetic counselors are a small but high-demand specialty, and Medicare coverage will accelerate hiring.
Examining the provided market data: Over the trailing 30 days (to April 30, 2026), $LH is down -1.49%, $DGX is nearly flat at -0.11%, while $AMN is up +12.43%. Over 7 days, LH and DGX are slightly negative (-0.37% and -0.25% respectively), while AMN gained +1.33%. AMN's strong 30-day performance (+12.43%) may reflect broader healthcare staffing recovery and the bill's introduction in January providing a sentiment lift. The lab stocks are near the middle of their 52-week ranges (LH $235.81-$293.72, current $262.83; DGX $164.65-$213.50, current $195.77), suggesting the bill's early-stage status has not yet been priced in significantly.
The timeline: The bill must pass the Senate Finance Committee, the full Senate, the House, and be signed by the President. With the effective date of January 1, 2027, there is a ~8-month runway from today. Given the 119th Congress runs through January 2027, passage by mid-2026 would allow CMS time to implement fee schedules. A realistic probability of passage is moderate — the bipartisan sponsorship and companion bill are positive signals, but this is not a high-priority leadership bill. If enacted, the impact on lab volumes would be gradual, likely materializing in late 2027 and 2028 as providers build capacity.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
direct reimbursement expansion under Medicare Part B for genetic counseling services, effective Jan 1, 2027
Who must act
Centers for Medicare & Medicaid Services (CMS) and all Medicare Administrative Contractors
What happens
Medicare beneficiaries can now access and bill for genetic counseling services from licensed/certified genetic counselors as a covered benefit, removing a prior barrier where services had to be furnished by or incident to a physician; this expands the addressable patient population for genetic testing orders that typically follow counseling
Stock impact
Labcorp's diagnostics segment, which generates ~$12B+ annual revenue from lab testing including genetic assays, benefits from increased test volume as Medicare patients receiving counseling are more likely to proceed with ordered genetic tests; Labcorp has a leading market position in hereditary cancer and prenatal genetic testing
What the bill does
direct reimbursement expansion under Medicare Part B for genetic counseling services, effective Jan 1, 2027
Who must act
Centers for Medicare & Medicaid Services (CMS) and all Medicare Administrative Contractors
What happens
Same mechanism as for LH: Medicare coverage of genetic counselor services removes a referral bottleneck, increasing the volume of genetic test orders from Medicare beneficiaries; genetic counselors will have a direct incentive to order companion diagnostic tests after counseling sessions
Stock impact
Quest Diagnostics' diagnostic information services segment (~$9B annual revenue) includes a substantial genetic testing portfolio; as the other dominant national lab player alongside Labcorp, Quest captures roughly similar market share in Medicare genetic test volumes; the expanded counseling coverage directly drives test order volume
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Veterans Community Care Scheduling Improvement Act
SUPPORT for Patients and Communities Reauthorization Act of 2025
ASAP Act
CHOICE for Veterans Act of 2025
Supporting Healthy Moms and Babies Act
Increasing Access to Lung Cancer Screening Act
Access to Breast Cancer Diagnosis Act of 2025
Thyroid Disease CARE Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.